NUDT22 and cancer: Co-targeting of pyrimidine salvage and de novo synthesis for cancer therapy has recently received renewed attention [34], and our data suggest that targeting pyrimidine de novo synthesis combined with NUDT22 inhibition might be an interesting novel therapeutic approach in the future.